This early-stage study tests a new MRI contrast agent called MT218 in 12 men with aggressive prostate cancer (Gleason score 8-10) who are scheduled for surgery. The goal is to see if this dye can better highlight dangerous tumors compared to standard MRI and PSMA-PET/CT scans. Pa…
Phase: PHASE1, PHASE2 • Sponsor: Songqi Gao • Aim: Diagnosis
Last updated May 14, 2026 12:01 UTC